TSLP and asthma: Lastly, we were unable to include the latest addition to the biologics portfolio for asthma therapy, the anti-TSLP-antibody Tezepelumab, as it has only been approved by the European Medicines Agency in the fall of 2022, and thus 12 month data was not yet available at the time of study conclusion.